

Gastric Carcinoma Marker (BY-1): sc-73568

BACKGROUND

Gastric carcinoma can develop in any part of the stomach and may spread from there to other organs, particularly the esophagus and the small intestine. It may also metastasize to nearby lymph nodes and organs such as the liver, pancreas, lungs, colon and ovaries. There are two major types of gastric carcinoma: intestinal type adenocarcinoma, in which tumor cells resemble irregular tubular structures that harbor pluristratification, multiple lumens and reduced stroma; and diffuse type adenocarcinoma, in which tumor cells are discohesive and secrete mucus that is then delivered to the interstitium, producing large pools of mucus. Gastric carcinoma cells produce unique proteins that are important in the identification and treatment of the disease.

REFERENCES

1. Chen, Y., Zhang, S., Chen, Y.P. and Lin, J.Y. 2006. Increased expression of angiogenin in gastric carcinoma in correlation with tumor angiogenesis and proliferation. *World J. Gastroenterol.* 12: 5135-5139.
2. Shi, L.H., Zhu, X.Q., Zhao, G.H., Xia, Y.B. and Zhang, Y.S. 2006. Expression of insulin-like growth factor binding protein-2 in gastric carcinoma and its relationship with cell proliferation. *World J. Gastroenterol.* 12: 6285-6289.
3. Hishinuma, M., Ohashi, K.I., Yamauchi, N., Kashima, T., Uozaki, H., Ota, S., Kodama, T., Aburatani, H. and Fukayama, M. 2006. Hepatocellular oncofetal protein, glypican-3 is a sensitive marker for α -fetoprotein-producing gastric carcinoma. *Histopathology* 49: 479-86.
4. Lee, K.H., Shin, S.J., Kim, K.O., Kim, M.K., Hyun, M.S., Kim, T.N., Jang, B.I., Kim, S.W., Song, S.K., Kim, H.S., Bae, S.H. and Ryoo, H.M. Relationship between E-cadherin, matrix metalloproteinase-7 gene expression and clinicopathological features in gastric carcinoma. *Oncol. Rep.* 16: 823-830.
5. Qazi, H.A., Manikandan, R., Foster, C.S. and Fordham, M.V. 2006. Testicular metastasis from gastric carcinoma. *Urology* 68: 890.e7-8.
6. Rojo, F., Tabernero, J., Albanell, J., Van Cutsem, E., Ohtsu, A., Doi, T., Koizumi, W., Shirao, K., Takiuchi, H., Ramon Cajal, S. and Baselga, J. 2006. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. *J. Clin. Oncol.* 24: 4309-4316.
7. Sakamoto, J., Oriuchi, N., Mochiki, E., Asao, T., Scott, A.M., Hoffman, E.W., Jungbluth, A.A., Matsui, T., Lee, F.T., Papenfuss, A., Kuwano, H., Takahashi, T., Endo, K. and Old, L.J. 2006. A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma. *Cancer Sci.* 97: 1248-1254.
8. Sakurai, Y., Yoshida, I., Tonomura, S., Inaba, K., Shoji, M., Nakamura, Y., Uyama, I., Komori, Y., Ochiai, M., Kamoshida, S. and Tsutsumi, Y. 2006. Clinical and prognostic significance of protein and gene expression of orotate phosphoribosyltransferase in gastric carcinoma. *Gan To Kagaku Ryoho* 33: 1111-1118.
9. Yashiro, M., Nishioka, N. and Hirakawa, K. 2006. Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. *Eur. J. Cancer* 42: 2397-2403.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

SOURCE

Gastric Carcinoma Marker (BY-1) is a mouse monoclonal antibody raised against five gastric cancer cell lines of human origin.

PRODUCT

Each vial contains 100 μ g IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Gastric Carcinoma Marker (BY-1) is recommended for detection of gastric carcinoma of human origin by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.